Rate of Viral Re-Suppression and Retention to Care Among PLHIV on Second-Line Antiretroviral Therapy at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia: A Retrospective Cohort Study

References

• UNAIDS/WHO. Global- HIB/AIDS Statistics, Fact Sheet. Vol. 3. UNAIDS; 2020.
   Google Scholar
• Estill J, Ford N, Salazar-vizcaya L, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. Lancet HIV. 2016;3018(16):1–8. doi:10.1016/S2352-3018(16)00016-3
   Web of Science ®Google Scholar
• Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One. 2017;12(7):1–15. doi:10.1371/journal.pone.0180761
   Web of Science ®Google Scholar
• WHO. The use of antiretroviral drugs for treating and preventing HIV infection; 2016: 99–152, 402. Available from: https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1&isAllowed=y. Accessed August 24, 2021.
   Google Scholar
• WHO. Ethiopia HIV Country Profile: 2016 WHO/HIV/2017. WHO; 2017.
   Google Scholar
• Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24(6):915–919. doi:10.1097/QAD.0b013e3283360976
   PubMed Web of Science ®Google Scholar
• Mocroft A, Phillips AN, Miller V, et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 2001;15(2):201–209. doi:10.1097/00002030-200101260-00009
   Web of Science ®Google Scholar
• Gumede SB, Fischer A, Venter WDF, Lalla-Edward ST. Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: a retrospective cohort data analysis. South African Med J. 2019;109(12):919–926. doi:10.7196/SAMJ.2019.v109i12.013895
   Web of Science ®Google Scholar
• Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15(1):1. doi:10.1186/s12879-015-1270-8.
   Web of Science ®Google Scholar
• Nsanzimana S, Semakula M, Ndahindwa V, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-3934-2
   Web of Science ®Google Scholar
• Stockdale AJ, Saunders MJ, Boyd MA, et al. Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in Sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(12):1846–1857. doi:10.1093/cid/cix1108
   Web of Science ®Google Scholar
• Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. Epidemilog Soc Sci. 2010;53(4):500–506.
   Google Scholar
• Desai M, Dikshit R, Patel D, Shah A. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res. 2013;4(4):215. doi:10.4103/2229-3485.120170
   PubMedGoogle Scholar
• Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014;209(5):711–720. doi:10.1093/infdis/jit411
   PubMed Web of Science ®Google Scholar
• Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14(1):1–7. doi:10.1186/1758-2652-14-14
   Web of Science ®Google Scholar
• Ethiopia Federal Ministry of Health. National consolidated guidelines for comprehensive HIV prevention, care and treatment. 2018: 1–238.
   Google Scholar
• Tsegaye AT, Wubshet M, Awoke T, Addis Alene K. Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study. BMJ Open. 2016;6(12):e012537. doi:10.1136/bmjopen-2016-012537
   PubMed Web of Science ®Google Scholar
• Seid A, Niguss Cherie KA, Ahmed K. Determinants of virologic failure among adults on second line antiretroviral therapy in Wollo, Amhara Regional State, Northeast Ethiopia. HIV/AIDS Res Palliat Care. 2020;12:697–706. doi:10.2147/HIV.S278603
   Google Scholar
• Worku ED, Asemahagn MA, Endalifer ML. Epidemiology of HIV infection in the Amhara region of Ethiopia, 2015 to 2018 surveillance data analysis. HIV/AIDS Res Palliat Care. 2020;12:307–314. doi:10.2147/HIV.S253194
   Google Scholar
• EPHI. Ethiopian Public Health Institution National HIV Reference Laboratory. EPHI; 2016.
   Google Scholar
• Medicne A societ laboratory. National review on HIV viral load testing and early infant diagnosis in Ethiopia; 2020. Available from: https://aslm.org/news-article/national-review-meeting-hiv-viral-load-testing-early-infant-diagnosis-ethiopia/. Accessed August 24, 2021.
   Google Scholar
• WHO. The Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. WHO; 2016.
   Google Scholar
• Onoya D, Nattey C, Budgell E, et al. Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing. Clin Epidemiol Res. 2017;31(5):205–212.
   Google Scholar
• Collier D, Iwuji C, Derache A, et al. Virological outcomes of second-line protease inhibitor – based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis. Clin Infect Dis MAJOR Artic Virol. 2017;64(8):1–11.
   Web of Science ®Google Scholar
• Shearer K, Evans D, Moyo F, et al. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017;22(2):221–231. doi:10.1111/tmi.12804
   PubMed Web of Science ®Google Scholar
• UNAIDS. 90-90-90An ambitious treatment target to help end the AIDS epidemic; 2014: 40. Available from: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed August 24, 2021.
   Google Scholar
• Mwasakifwa GE, Moore C, Carey D, et al. Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018;32(3):357–361. doi:10.1097/QAD.0000000000001688
   Web of Science ®Google Scholar
• Thu N, Kyaw T, Kumar AMV, et al. Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar. Glob Health Action. 2017;10(1):1290916. doi:10.1080/16549716.2017.1290916
   Web of Science ®Google Scholar
• Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital signs: HIV transmission along the continuum of care — United States, 2016. Morbid Mortal Wkly Rep. 2019;68(11):267–272.
   PubMed Web of Science ®Google Scholar
• Collier D, Iwuji C, Derache A, et al. Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence Rural South African setting: a competing-risks prospective cohort analysis. Clin Infect Dis. 2017;64(8):1006–1016. doi:10.1093/cid/cix015
   PubMed Web of Science ®Google Scholar
• Onoya D, Hirasen K, Berg L, Van Den MJ, Long LC, Fox MP. Adverse drug reactions among patients initiating second ‑ line antiretroviral therapy in South Africa. Drug Saf. 2018;41(12):1343–1353. doi:10.1007/s40264-018-0698-3
   Web of Science ®Google Scholar
• Häggblom A, Santacatterina M, Neogi U, et al. Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. PLoS One. 2017;12(7):1–14. doi:10.1371/journal.pone.0180140
   Web of Science ®Google Scholar
• Thao VP, Quang VM, Wolbers M, et al. Second-line HIV therapy outcomes and determinants of mortality at the largest HIV referral center in Southern Vietnam. Med obs study. 2015;94(43)1–8, doi:10.1097/MD.0000000000001715.
   Google Scholar
• Ssempijja V, Nakigozi G, Chang L, et al. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17:1–10.
   Web of Science ®Google Scholar
• Murphy RA, Court R, Maartens G, Sunpath H. Second-line antiretroviral therapy in Sub-Saharan Africa. AIDS Res Human Retroviruses. 2017;33(12):1181–1184. doi:10.1089/aid.2017.0134
   Web of Science ®Google Scholar
• Petersena ML, Linh Trana EH, Gengb SJ. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. NIH Public Access. 2015;28(14):2097–2107.
   Google Scholar
• Moges NA, Olubukola A, Micheal O, Berhane Y. HIV patients retention and attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(439):1–24.
   Google Scholar
• Findley MG, Denly M. External validity. Ann Rev Polit Sci. 2020;24:365–393.
   Web of Science ®Google Scholar